Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditions

Therapeutic Drug Monitoring

Volumn 32, Issue 2, 2010, Pages 237-241

  Marquet, Pierre ^a,b,c   Sauvage, François Ludovic ^a,b   Loustaud Ratti, Véronique ^a   Babany, Gérard ^d   Rousseau, Annick ^b,c   Lachĝtre, Gérard ^c  

^a LIMOGES UNIVERSITY HOSPITAL   (France)

^b INSERM   (France)

^c UNIVERSITY OF LIMOGES   (France)

^d Produits Roche   (France)

Author keywords

Blood collection tubes; LC MS MS; Preanalytical; Ribavirin; Stability; Therapeutic drug monitoring

Indexed keywords

EDETIC ACID; HEPARIN DERIVATIVE; LITHIUM; RIBAVIRIN;

ARTICLE; BLOOD SAMPLING; CENTRIFUGATION; DRUG BLOOD LEVEL; HEPATITIS C; HUMAN; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; PRIORITY JOURNAL; STORAGE TEMPERATURE; TIME; TUBE; BLOOD; CHEMICAL ANALYSIS; COMPARATIVE STUDY; DRUG STABILITY; LABORATORY DIAGNOSIS; PROCEDURES; STANDARDS;

BLOOD SPECIMEN COLLECTION; CHEMISTRY TECHNIQUES, ANALYTICAL; DRUG STABILITY; HUMANS; RIBAVIRIN; SPECIMEN HANDLING;

EID: 77950225019     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0b013e3181d3f686     Document Type: Article

References (10)

1. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology. 2008;47:1453-1461.
2. Loustaud-Ratti V, Rousseau A, Marquet P, et al. Ribavirin in chronic hepatitis C: past and future. Expert Rev Anti Infect Ther. 2009;7: 249-253.
3. Loustaud-Ratti V, Stanke-Labesque F, Marquet P, et al. Optimizing ribavirin dosage: a new challenge to improve treatment efficacy in genotype 1 hepatitis C patients. Gastroenterol Clin Biol. 2009;33: 580-583.
4. Sauvage FL, Stanke-Labesque F, Gagnieu MC, et al. Feasibility of ribavirin therapeutic drug monitoring in hepatitis C. Ther Drug Monit. 2009;31:374-381.
5. Dixit NM, Perelson AS. The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci. 2006;63:832-842.
6. Jen JF, Glue P, Gupta S, et al. Population pharmacokinetic and pharmacodynamic analysis of ribavirin in patients with chronic hepatitis C. Ther Drug Monit. 2000;22:555-565.
7. Larrat S, Stanke-Labesque F, Plages A, et al. Ribavirin quantification in combination treatment of chronic hepatitis C. Antimicrob Agents Chemother. 2003;47:124-129.
8. Loregian A, Scarpa MC, Pagni S, et al. Measurement of ribavirin and evaluation of its stability in human plasma by high-performance liquid chromatography with UV detection. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;856:358-364.
9. Jen J, Laughlin M, Chung C, et al. Ribavirin dosing in chronic hepatitis C: application of population pharmacokinetic-pharmacodynamic models. Clin Pharmacol Ther. 2002;72:349-361.
10. Dahari H, Markatou M, Zeremski M, et al. Early ribavirin pharmaco-kinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol. 2007;47:23-30.